助手标题  
全文文献 工具书 数字 学术定义 翻译助手 学术趋势 更多
查询帮助
意见反馈
   gradient release 的翻译结果: 查询用时:0.007秒
图标索引 在分类学科中查询
所有学科
有机化工
中药学
更多类别查询

图标索引 历史查询
 

gradient release
相关语句
  梯度释药
     Studies on the Manufacture Technology of Ganxinsuhe PH Dependent gradient release pellet
     冠心苏合丸PH依赖型梯度释药微丸的制备工艺
短句来源
     AIM To prepare heart protecting musk pH dependent gradient release pellets and investigate the drug release in vitro and in vivo .
     目的 制备麝香保心pH依赖型梯度释药微丸并进行体内外考察。
短句来源
     OBJECTIVE To study the gastrointestinal transit and disintegration of pH dependent gradient release Shexiang Baoxin pellets in vo lunteers.
     目的 探讨 pH依赖型梯度释药麝香保心微丸在健康志愿者体内的转运和崩解情况。
短句来源
     CONCLUSION pH dependent gradient release Shexiang Baoxin pellets had the characteristic of pH dependent gradient release and dispersion. It would b e reasonable and suitable for the pH dependent gradient release pellets to be taken at intervals of 12 h.
     结论 pH依赖型梯度释药麝香保心微丸在人体内具有pH依赖性梯度崩解溶散的特征 ,预计该制剂1 2h服药一次是可行的
短句来源
     Guanxinsuhe pill is used in this article as a method medicine of compound recipe tradition Chinese medicine preparation,we disign and manufacture PH dependent gradient release capsule.
     本文用冠心苏舍丸作为复方中药制剂模型药物,设计并研制PH依赖型梯度释药胶囊。
短句来源
  “gradient release”译为未确定词的双语例句
     Three pH-dependent gradient release pellets were prepared by using HPMC and aqueous dispersingmethacrylic acid copolymers as coating, respectively.
     分别以HPMC和pH依赖型丙烯酸树脂(Eudragit)的肠溶水分散体为包衣材料制备了3种微丸。
短句来源
  相似匹配句对
     Intelligent Release
     智能脱扣器
短句来源
     gradient elution;
     梯度洗脱;
短句来源
     Gradient of the Text
     文本的梯度
短句来源
     NEW RELEASE
     新片推荐
短句来源
     Studies on Jiang-Gui pH Dependent Gradient-release Capsules
     姜桂pH依赖型梯度释药胶囊的研究
短句来源
查询“gradient release”译词为用户自定义的双语例句

    我想查看译文中含有:的双语例句
例句
没有找到相关例句


Object To investigate the release of pH dependent gradient releasing heart protecting musk pellets (GRHPMP) in vitro. Methods The pH dependent GRHPMP was prepared by coating with hydroxy propylmethy cellulose, Eudragit ○R L 30D 55 and Eudragit ○R L100/S100, repectively. The release of borneol and total ginsenoside from GRHPMP were determined according to method described in Chinese Pharmacopoeia (2000 ed) at simulated gastrointestinal pH conditions. Results The f 2 value...

Object To investigate the release of pH dependent gradient releasing heart protecting musk pellets (GRHPMP) in vitro. Methods The pH dependent GRHPMP was prepared by coating with hydroxy propylmethy cellulose, Eudragit ○R L 30D 55 and Eudragit ○R L100/S100, repectively. The release of borneol and total ginsenoside from GRHPMP were determined according to method described in Chinese Pharmacopoeia (2000 ed) at simulated gastrointestinal pH conditions. Results The f 2 value of release data of borneol and total ginsenoside was 79 6. Conclusion The result suggested that, in vitro, the liposoluble borneol and watersoluble total ginsenoside could release simultaneously at a sustained rate.

目的 考察麝香保心 p H依赖型梯度释药微丸的体外释放度。方法 分别以 HPMC,Eudragit○RL - 30 D- 5 5 ,Eudragit○RL 10 0 / S10 0为包衣材料制备 p H依赖型梯度释药微丸 ,以冰片和人参总皂苷为检测指标 ,按照《中国药典》2 0 0 0年版溶出度测定法 ,在模拟人体胃肠道 p H变化条件下进行释放度实验。结果 冰片和人参总皂苷释放度的f2 值为 79.6。结论 脂溶性成分冰片和水溶性成分人参总皂苷在缓释的同时基本上达到了同步释放

AIM To prepare heart protecting musk pH dependent gradient release pellets and investigate the drug release in vitro and in vivo . METHODS The pH dependent gradient release pellet system was prepared by using HPMC, Eudragit L 30D 55 and Eudragit L100 Eudragit S100 ( 1∶5 ) combinations as coater. The release of borneol and total ginsenoside from pH dependent gradient release pellets were determined according to the method of Pharmacopoeia of...

AIM To prepare heart protecting musk pH dependent gradient release pellets and investigate the drug release in vitro and in vivo . METHODS The pH dependent gradient release pellet system was prepared by using HPMC, Eudragit L 30D 55 and Eudragit L100 Eudragit S100 ( 1∶5 ) combinations as coater. The release of borneol and total ginsenoside from pH dependent gradient release pellets were determined according to the method of Pharmacopoeia of the People's Republic of China (2000) in the simulated gastrointestinal pH conditions. The gastrointestinal transit and disintegration of pellets was investigated by using γ scintigraphic trace in volunteers. The pharmacokinetics of borneol of heart protecting musk pH dependent gradient release pellets was studied in 6 healthy volunteers by GC methods. RESULTS The f 2 value of release data of borneol and total ginsenoside of the heart protecting musk pH dependent gradient release pellets was 79 6 in the simulated gastrointestinal pH conditions. The γ scintigraphic trace evaluation demonstrated that the pellets coated with HPMC, Eudragit L 30D 55 or Eudragit L100 Eudragit S100 ( 1∶5 ) combinations can disintegrate in stomach, duodenum and jejunum or ileum. The gastrointestinal transit time of pellets was about 5 hours in fasted state and about 6 hours in fed state. The concentration time curves of borneol of heart protecting musk pills fit in two compartment model. The pharmacokinetics data showed that borneol had a short time of absorption and elimination. The mean residence time (MRT) of borneol of heart protecting musk pills was 2 61 hours. The plasma concentration of borneol of heart protecting musk sustained release capsule which consisted of three kinds of pellets coated with HPMC, Eudragit L 30D 55 or Eudragit L100 Eudragit S100 ( 1∶5 ) combinations was steadier than those of heart protecting musk pills, its C max was lower than and T max was near to those of heart protecting musk pills, its MRT was 4 0 hours, and its relative bioavailability was 96%. CONCLUSION The lipidsoluble borneol and watersoluble total ginsenoside of heart protecting musk pH dependent gradient release pellets can release simultaneously while sustained releasing in vitro . The heart protecting musk pH dependent gradient release pellets had the characteristics of pH dependent gradient releasing and disintegration while transiting in gastrointestinal tract. A characteristic of gradient sustained release was shown in the concentration time curves of borneol of heart protecting musk sustained release capsule in volunteers.

目的 制备麝香保心pH依赖型梯度释药微丸并进行体内外考察。方法 分别以HPMC ,EudragitL 30D 5 5和EudragitL10 0 EudragitS10 0 (1∶5 )为包衣材料制备pH依赖型梯度释药微丸 ,并进行体外释放度、胃肠道转运和体内药代动力学研究。结果 冰片和人参总皂苷体外释放度的f2 值为 79 6 ,3种包衣微丸分别在胃、十二指肠和空回肠部崩解 ,由 3种微丸组成的缓释胶囊中冰片的Tmax与原丸剂相近 ,而Cmax明显降低 ,相对生物利用度为 96 %。结论缓释胶囊中的冰片和人参总皂苷在体外可同步缓释 ,在体内具有pH依赖性崩解溶散的特征 ,冰片作为指标性成分具有梯度缓释的药代动力学特点。

Object To investigate the pharmacokinetic parameters of Musk Protecting Heart Pellets with pH-dependent gradient-release (MPHP-pH) and Musk Protecting Heart Pills (MPHP). Methods The cardiac muscle nutritional blood flow in rat was measured as effective index. Results It was one-compartment model when the rat was ig MPHP. The minimal effecting dose was 0.54 mg/kg, the present half-life, the elimination half-life, medicinal effect and the peak time of effective action were 0.53, 1.21, 3.48 and...

Object To investigate the pharmacokinetic parameters of Musk Protecting Heart Pellets with pH-dependent gradient-release (MPHP-pH) and Musk Protecting Heart Pills (MPHP). Methods The cardiac muscle nutritional blood flow in rat was measured as effective index. Results It was one-compartment model when the rat was ig MPHP. The minimal effecting dose was 0.54 mg/kg, the present half-life, the elimination half-life, medicinal effect and the peak time of effective action were 0.53, 1.21, 3.48 and 1.13 h, respectively. The absorption half-life, elimination half-life and peak time of effective dose were 0.23, 1.47 and 0.88 h, respectively. Statistical moment analysis showed that the mean residence time mean residence time (MRT) of effective action were 5.05 h for MPHP-pH and 2.33 h for MPHP, the MRT of effective dose were 7.70 h for MPHP-pH and 3.21 h for MPHP. The relative bioavailability of effective dose for MPHP-pH was 104.03%. Conclusion MPHP has the characteristics of fast absorption, fast eliminationand short effective action time. Whereas MPHP-pH has the characteristics of fast absorption, protonged and relaxed effective action compared with MPHP.

目的 探讨麝香保心 p H依赖型梯度释药微丸和麝香保心丸的药效动力学参数。方法 以大鼠心肌营养性血流量为效应指标进行测定。结果 麝香保心丸在大鼠体内呈一室模型特征 ,其最低起效剂量为 0 .5 4mg/ kg,效应呈现半衰期为 0 .5 3h,效应消除半衰期为 1.2 1h,药效作用期为 3.48h,效应达峰时间为 1.13h,效量吸收半衰期为 0 .2 3h,消除半衰期为 1.47h,达峰时间为 0 .88h。统计矩结果表明麝香保心 p H依赖型梯度释药微丸和麝香保心丸的平均效应维持时间分别为 5 .0 5 h和 2 .33h,效量平均滞留时间分别为 7.70 h和 3.2 1h,麝香保心 p H依赖型梯度释药微丸的效量相对生物利用度为 10 4.0 3%。结论 麝香保心丸在体内具有吸收快、消除快和作用维持时间较短的特点 ,而麝香保心 p H依赖型梯度释药微丸在体内具有起效迅速、药效持久、缓和的特征。

 
<< 更多相关文摘    
图标索引 相关查询

 


 
CNKI小工具
在英文学术搜索中查有关gradient release的内容
在知识搜索中查有关gradient release的内容
在数字搜索中查有关gradient release的内容
在概念知识元中查有关gradient release的内容
在学术趋势中查有关gradient release的内容
 
 

CNKI主页设CNKI翻译助手为主页 | 收藏CNKI翻译助手 | 广告服务 | 英文学术搜索
版权图标  2008 CNKI-中国知网
京ICP证040431号 互联网出版许可证 新出网证(京)字008号
北京市公安局海淀分局 备案号:110 1081725
版权图标 2008中国知网(cnki) 中国学术期刊(光盘版)电子杂志社